ReviewBioMed research international2013
Microvesicles as potential ovarian cancer biomarkers.
Review in BioMed research international, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- Circulating endothelial-derived activated microparticle: a useful biomarker for predicting one-year mortality in patients with advanced non-small cell lung cancer.BioMed research international · 2014Trial
- Extracellular Vesicles Drive Invasive Characteristics and Matrix Remodelling in Organotypic Models of Colorectal Cancer Progression.Journal of extracellular biology · 2026Article
- Extracellular Vesicle-Based Strategies for Tumor Immunotherapy.Pharmaceutics · 2025Review
- Metastatic Dissemination: Role of Tumor-Derived Extracellular Vesicles and Their Use as Clinical Biomarkers.International journal of molecular sciences · 2023Review
- The potential applications of microparticles in the diagnosis, treatment, and prognosis of lung cancer.Journal of translational medicine · 2022Review
- Article
- Machine Learning-Based Risk Prediction of Critical Care Unit Admission for Advanced Stage High Grade Serous Ovarian Cancer Patients Undergoing Cytoreductive Surgery: The Leeds-Natal Score.Journal of clinical medicine · 2021Article
- Article
- Extracellular Vesicles as Mediators of Cancer Disease and as Nanosystems in Theranostic Applications.Cancers · 2021Review
- Proteomic Profiling of Ectosomes Derived from Paired Urothelial Bladder Cancer and Normal Cells Reveals the Presence of Biologically-Relevant Molecules.International journal of molecular sciences · 2021Article
- Circulating large extracellular vesicles carrying CA9 in the diagnosis and prognosis of clear-cell renal cell carcinoma.Clinical and translational medicine · 2021Article
- Roles of Microvesicles in Tumor Progression and Clinical Applications.International journal of nanomedicine · 2021Review
- Breast Cancer Derived Extracellular Vesicles in Bone Metastasis Induction and Their Clinical Implications as Biomarkers.International journal of molecular sciences · 2020Review
- Ovarian cancer-derived extracellular vesicles affect normal human fibroblast behavior.Cancer biology & therapy · 2018Article
- The biology of extracellular microvesicles.Traffic (Copenhagen, Denmark) · 2018Review
- Exosomes: new molecular targets of diseases.Acta pharmacologica Sinica · 2018Review
- Dysregulated fibronectin trafficking by Hsp90 inhibition restricts prostate cancer cell invasion.Scientific reports · 2018Article
- New role of hypoxia in pathophysiology of multiple myeloma through miR-210.EXCLI journal · 2018Article
- Fibroblast growth factor-6 enhancesF1000Research · 2018Article
- The emerging roles and therapeutic potential of exosomes in epithelial ovarian cancer.Molecular cancer · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although the incidence of ovarian cancer is low (i.e., less than 5% in European countries), it is the most lethal gynecologic malignancy and typically has a poor prognosis. To ensure optimal survival, it is important to diagnose this condition when the pathology is confined to the ovary. However, this is difficult to achieve because the first specific symptoms appear only during advanced disease stages. To date, the biomarker mainly used for the diagnosis and prognosis of ovarian cancer is CA125; however, this marker has a low sensitivity and specificity and is associated with several other physiological and pathological conditions. No other serum ovarian cancer markers appear to be able to replace or complement CA125, and the current challenge is therefore to identify novel markers for the early diagnosis of this disease. For this purpose, studies have focused on the microvesicles (MVs) released from tumor cells. MVs may represent an ideal biomarker because they can be easily isolated from blood, and they have particular features (mainly regarding microRNA profiles) that strongly correlate with ovarian cancer stage and may be effective for early diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.